Your search returned 35 studies. (Get alerts for new studies):
- Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Cancer
4 Locations available
- Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer
2 Locations available
- AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or O
Conditions: brca1 Mutation Carrier - brca2 Mutation Carrier - Breast Cancer - Hereditary Breast/Ovarian Cancer (brca1, brca2) - Ovarian Cancer
1 Location available
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With M
Conditions: Estrogen Receptor-negative Breast Cancer - HER2-negative Breast Cancer - Progesterone Receptor-negative Breast Cancer - Stage IV Breast Cancer - Triple-negative Breast Cancer
11 Locations available
- Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Conditions: Breast Cancer
3 Locations available
- A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Conditions: Triple Negative Breast Cancer
2 Locations available
- Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Conditions: Breast Cancer
1 Location available
- Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Conditions: Breast Cancer
14 Locations available
- Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer
12 Locations available
- A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
Conditions: Triple Negative Breast Cancer
1 Location available
- MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer - Inflammatory Breast Cancer - Stage I Breast Cancer - Stage II Breast Cancer - Stage IIIA Breast Cancer - Stage IIIB Breast Cancer - Stage IIIC Breast Cancer - Triple-negative Breast Cancer
1 Location available
- Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Conditions: Triple Negative Breast Cancer
1 Location available
- PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Conditions: Breast Cancer
26 Locations available
- Estrogen for Triple Negative Breast Cancer
Conditions: Female Breast Cancer
1 Location available
- Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Conditions: Breast Cancer
1 Location available
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Conditions: Breast Cancer
5 Locations available
- Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer
Conditions: Ovarian Cancer - Primary Peritoneal Cancer - Fallopian Tube Cancer
5 Locations available
- Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer
Conditions: Breast Neoplasms
1 Location available
- A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer - Progesterone Receptor Negative (PR-Negative) Breast Cancer - Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer - Brain Metastases
13 Locations available
- Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast
Conditions: Breast Cancer
1 Location available
- Re-expression of ER in Triple Negative Breast Cancers
Conditions: Breast Cancer - Breast Tumors - Breast Neoplasms
1 Location available
- Entinostat and Anastrozole or Tamoxifen in Treating Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery
Conditions: Breast Cancer
18 Locations available
- RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Breast Cancer
1 Location available
- A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Conditions: Breast Neoplasms - Breast Cancer - Cancer of the Breast
3 Locations available
- Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
Conditions: Breast Cancer
1 Location available
- Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery
Conditions: Recurrent Breast Cancer - Stage IA Breast Cancer - Stage IB Breast Cancer - Stage II Breast Cancer - Stage IIIA Breast Cancer - Stage IIIB Breast Cancer - Stage IIIC Breast Cancer - Stage IV Breast Cancer - Triple-negative Breast Cancer
1 Location available
- A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-
Conditions: Breast Cancer
4 Locations available
- Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Conditions: Multiple Myeloma - Non-Hodgkin's Lymphoma - Glioblastoma Multiforme - Head and Neck Squamous Cell Cancer - Triple Negative Breast Cancer - Hormone Receptor-Positive Breast Cancer - Castration-Resistant Prostate Cancer - Ewing's Family of Sarcomas
2 Locations available
- Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer - HER2-negative Breast Cancer - Male Breast Cancer - Progesterone Receptor-negative Breast Cancer - Stage IA Breast Cancer - Stage IB Breast Cancer - Stage II Breast Cancer - Stage IIIA Breast Cancer - Stage IIIB B
1 Location available
- A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Conditions: ER Positive, Her2 Negative Breast Cancer Patients - Triple Negative Breast Cancer Patients
36 Locations available
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Conditions: Colorectal Cancer - Squamous Cell Head and Neck Cancer - Non-small Cell Lung Cancer - Triple Negative Breast Cancer - Other Tumors With EGFR Dependence
2 Locations available
- Study of ABT-700 in Subjects With Advanced Solid Tumors
Conditions: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
3 Locations available
- Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer
Conditions: Breast Cancer
1 Location available
- Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Tripl
Conditions: Inflammatory Breast Cancer - Stage II Breast Cancer - Stage IIIA Breast Cancer - Stage IIIB Breast Cancer - Stage IIIC Breast Cancer - Triple-negative Breast Cancer
2 Locations available
- Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Conditions: Breast Cancer
1 Location available
|